Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial (Q90181685)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31537486%20AND%20SRC:MED&resulttype=core&format=json

12 April 2020

title

Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31537486%20AND%20SRC:MED&resulttype=core&format=json

12 April 2020

1 reference

Asra Ahmed

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31537486%20AND%20SRC:MED&resulttype=core&format=json

12 April 2020

Samuel A Merrill

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31537486%20AND%20SRC:MED&resulttype=core&format=json

12 April 2020

Fares Alsawah

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31537486%20AND%20SRC:MED&resulttype=core&format=json

12 April 2020

Paula Bockenstedt

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31537486%20AND%20SRC:MED&resulttype=core&format=json

12 April 2020

Erica Campagnaro

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31537486%20AND%20SRC:MED&resulttype=core&format=json

12 April 2020

Sumana Devata

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31537486%20AND%20SRC:MED&resulttype=core&format=json

12 April 2020

Scott D Gitlin

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31537486%20AND%20SRC:MED&resulttype=core&format=json

12 April 2020

Mark Kaminski

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31537486%20AND%20SRC:MED&resulttype=core&format=json

12 April 2020

Alice Cusick

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31537486%20AND%20SRC:MED&resulttype=core&format=json

12 April 2020

Tycel Phillips

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31537486%20AND%20SRC:MED&resulttype=core&format=json

12 April 2020

Suman Sood

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31537486%20AND%20SRC:MED&resulttype=core&format=json

12 April 2020

Moshe Talpaz

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31537486%20AND%20SRC:MED&resulttype=core&format=json

12 April 2020

Albert Quiery

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31537486%20AND%20SRC:MED&resulttype=core&format=json

12 April 2020

Philip S Boonstra

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31537486%20AND%20SRC:MED&resulttype=core&format=json

12 April 2020

Ryan A Wilcox

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31537486%20AND%20SRC:MED&resulttype=core&format=json

12 April 2020

publication date

16 September 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31537486%20AND%20SRC:MED&resulttype=core&format=json

12 April 2020

published in

The Lancet. Haematology.

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31537486%20AND%20SRC:MED&resulttype=core&format=json

12 April 2020

volume

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31537486%20AND%20SRC:MED&resulttype=core&format=json

12 April 2020

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31537486%20AND%20SRC:MED&resulttype=core&format=json

12 April 2020

page(s)

e630-e637

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31537486%20AND%20SRC:MED&resulttype=core&format=json

Hemophagocytic lymphohistiocytosis: advances in pathophysiology, diagnosis, and treatment

12 April 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2819%2930156-5

7 January 2021

How I treat hemophagocytic lymphohistiocytosis in the adult patient

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2819%2930156-5

7 January 2021

Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2819%2930156-5

7 January 2021

Confirmed efficacy of etoposide and dexamethasone in HLH treatment: long-term results of the cooperative HLH-2004 study.

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2819%2930156-5

7 January 2021

Haemophagocytic lymphohistiocytosis in adults: a multicentre case series over 7 years.

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2819%2930156-5

7 January 2021

Prognostic factors and outcomes of adults with hemophagocytic lymphohistiocytosis

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2819%2930156-5

7 January 2021

Reactive hemophagocytic syndrome in adults: a retrospective analysis of 162 patients.

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2819%2930156-5

7 January 2021

Hemophagocytic lymphohistiocytosis: clinical analysis of 103 adult patients

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2819%2930156-5

7 January 2021

A prospective quality improvement initiative in adult hemophagocytic lymphohistiocytosis to improve testing and a framework to facilitate trigger identification and mitigate hemorrhage from retrospective analysis

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2819%2930156-5

7 January 2021

An animal model of hemophagocytic lymphohistiocytosis (HLH): CD8+ T cells and interferon gamma are essential for the disorder

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2819%2930156-5

7 January 2021

Neutralization of IFNgamma defeats haemophagocytosis in LCMV-infected perforin- and Rab27a-deficient mice

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2819%2930156-5

7 January 2021

Janus kinase inhibition lessens inflammation and ameliorates disease in murine models of hemophagocytic lymphohistiocytosis

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2819%2930156-5

7 January 2021

GATA-3 expression identifies a high-risk subset of PTCL, NOS with distinct molecular and clinical features

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2819%2930156-5

7 January 2021

STXBP2 mutations in children with familial haemophagocytic lymphohistiocytosis type 5

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2819%2930156-5

7 January 2021

Spectrum of clinical presentations in familial hemophagocytic lymphohistiocytosis type 5 patients with mutations in STXBP2.

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2819%2930156-5

7 January 2021

Soluble hemoglobin-haptoglobin scavenger receptor CD163 as a lineage-specific marker in the reactive hemophagocytic syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2819%2930156-5

7 January 2021

Malignancy-associated hemophagocytic lymphohistiocytosis in adults: Relation to hemophagocytosis, characteristics, and outcomes

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2819%2930156-5

7 January 2021

Etoposide selectively ablates activated T cells to control the immunoregulatory disorder hemophagocytic lymphohistiocytosis.

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2819%2930156-5

7 January 2021

Involvement of interferon-gamma and macrophage colony-stimulating factor in pathogenesis of haemophagocytic lymphohistiocytosis in adults

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2819%2930156-5

7 January 2021

Elevated circulating levels of interferon-γ and interferon-γ-induced chemokines characterise patients with macrophage activation syndrome complicating systemic juvenile idiopathic arthritis.

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2819%2930156-5

7 January 2021

Increased serum levels of interferon-gamma-inducible protein 10 and monokine induced by gamma interferon in patients with haemophagocytic lymphohistiocytosis

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2819%2930156-5

7 January 2021

Myeloproliferative Neoplasms: A Contemporary Review

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2819%2930156-5

7 January 2021

Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2819%2930156-5

7 January 2021

Jakinibs for the treatment of immune dysregulation in patients with gain-of-function signal transducer and activator of transcription 1 (STAT1) or STAT3 mutations

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2819%2930156-5

7 January 2021

Ruxolitinib for treatment of refractory hemophagocytic lymphohistiocytosis

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2819%2930156-5

7 January 2021

Ruxolitinib as first-line treatment in secondary hemophagocytic lymphohistiocytosis: A single patient experience.

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2819%2930156-5

7 January 2021

Ruxolitinib as First-Line Treatment in Secondary Hemophagocytic Lymphohistiocytosis: A Second Experience.

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2819%2930156-5

7 January 2021

Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2819%2930156-5

7 January 2021

10.1016/S2352-3026(19)30156-5

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31537486%20AND%20SRC:MED&resulttype=core&format=json

12 April 2020

1 reference